Wow Dxb still in phase 3 Trial results in 2025 ( 2nd interim results ) Im confident Per will secure a Big Pharma or two while we are in Phase 2b because if the 6 month readout is successful the Partner will carry on funding the next 6 months with the 45 boys But If the readout is spectacular Per will go to the FDA for accelerated approval and commercialisation ..Big Pharma will have to pay a great deal more.. DXB : FSGS market is >200,000 @US $120,000 per annum.. Note Per has a much bigger market with multiple indications $$ Not rubbishing DXB or PYC just trying to get a handle what PER will be worth in Time IMO: >$5
